Candel Therapeutics (CADL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of four Class II directors: Edward J. Benz, Jr., Paul B. Manning, Maha Radhakrishnan, and Paul Peter Tak, with board recommending a vote in favor.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended by the board.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all four nominees for Class II director positions.
Audit committee and external auditor matters
Proposal to ratify KPMG LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Candel Therapeutics
- Virtual meeting to elect directors, ratify auditor, and review governance and compensation.CADL
Proxy filing29 Apr 2026 - Aglatimagene and linoserpaturev show strong efficacy and safety across multiple cancer types.CADL
Corporate presentation16 Apr 2026 - Lead programs show strong efficacy and safety in major cancers, with broad commercial potential.CADL
Corporate presentation23 Mar 2026 - Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028.CADL
Q4 202512 Mar 2026 - Pivotal phase III success in prostate cancer and promising glioma data drive 2024 milestones.CADL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Late-stage viral immunotherapies show strong survival gains in multiple solid tumors.CADL
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Viral immunotherapies show strong survival gains in late-stage cancer trials, with key data imminent.CADL
Jefferies London Healthcare Conference 202413 Jan 2026 - Significant disease-free survival and response gains with favorable safety profile.CADL
Study Result11 Jan 2026 - Up to $300M in securities registered, including $50M at-the-market stock via Jefferies.CADL
Registration Filing16 Dec 2025